Monocytes as a convergent nanoparticle therapeutic target for cardiovascular diseases.

Authors:
Aldarondo D; Wayne E.

Journal:
Adv Drug Deliv Rev

Publication Year: 2022

DOI:
10.1016/j.addr.2022.114116

PMCID:
PMC9359644

PMID:
35085623

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Adv Drug Deliv Rev

Abbreviation: Adv Drug Deliv Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Drug Therapy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics.
Kang DD; Li H; Dong Y. (2023) - Transparency Score: 3/6
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery.
Han G; Noh D; Lee H and 4 more (2023) - Transparency Score: 3/6
Imaging drug delivery to the lungs: Methods and applications in oncology.
Man F; Tang J; Swedrowska M and 2 more (2022) - Transparency Score: 3/6
In vivo fate and intracellular trafficking of vaccine delivery systems.
Lee J; Kim D; Byun J and 3 more (2022) - Transparency Score: 3/6
Targeting the liver in dementia and cognitive impairment: Dietary macronutrients and diabetic thera…
Hunt NJ; Wahl D; Westwood LJ and 3 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of Competing Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

Evidence found in paper:

"Funding Sources Research reported in this publication was supported by National Institute of General Medical Sciences of the National Institutes of Health under award numbers 1 R35 GM142957-01, 5T32GM133353-02, and the GEM Fellowship."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025